Bortezomib
- Generic Name
- Bortezomib
- Brand Names
- Velcade, Bortezomib Accord, Bortezomib Hospira, Bortezomib Fresenius Kabi, Bortezomib Sun
- Drug Type
- Small Molecule
- Chemical Formula
- C19H25BN4O4
- CAS Number
- 179324-69-7
- Unique Ingredient Identifier
- 69G8BD63PP
- Background
Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib.
Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, and solid tumours.
- Indication
Bortezomib is indicated for the treatment of adults with multiple myeloma or mantle cell lymphoma.
- Associated Conditions
- Mantle Cell Lymphoma (MCL), Multiple Myeloma (MM)
- Associated Therapies
- -
ADVANCE: An Observational Study To Determine Bortezomib Safety and Effectiveness at First Relapse After Participation In First Line HOVON-49/50 Clinical Studies.
- First Posted Date
- 2007-02-27
- Last Posted Date
- 2015-04-16
- Lead Sponsor
- Janssen-Cilag B.V.
- Target Recruit Count
- 11
- Registration Number
- NCT00440479
Velcade Plus ICE for Patients With Relapsed Classical Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2007-02-23
- Last Posted Date
- 2012-07-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 14
- Registration Number
- NCT00439361
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant
- Conditions
- Interventions
- First Posted Date
- 2007-02-23
- Last Posted Date
- 2019-09-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT00439556
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Bortezomib, Cyclophosphamide, Dexamethasone, and Thalidomide in Treating Patients With Newly Diagnosed, Previously Untreated Multiple Myeloma
- Conditions
- First Posted Date
- 2007-02-22
- Last Posted Date
- 2009-03-13
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 43
- Registration Number
- NCT00438841
- Locations
- 🇺🇸
Oregon Health and Science University Cancer Institute, Portland, Oregon, United States
🇺🇸Desert Regional Medical Center Comprehensive Cancer Center, Palm Springs, California, United States
🇺🇸Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, Los Angeles, California, United States
The Efficacy of Velcade on Bone Tissue During Myelomatosis (Bone Marrow Cancer)
- Conditions
- First Posted Date
- 2007-02-16
- Last Posted Date
- 2009-07-08
- Lead Sponsor
- Vejle Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT00436059
- Locations
- 🇩🇰
University Hospital Odense, Odense, Denmark
🇩🇰Vejle Hospital, Vejle, Denmark
Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2007-02-12
- Last Posted Date
- 2014-10-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 77
- Registration Number
- NCT00433537
- Locations
- 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States
A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed Myeloma
- Conditions
- First Posted Date
- 2007-02-06
- Last Posted Date
- 2011-08-12
- Lead Sponsor
- Peter MacCallum Cancer Centre, Australia
- Target Recruit Count
- 40
- Registration Number
- NCT00431990
- Locations
- 🇦🇺
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
An Efficacy and Safety Study of Bortezomib Re-treatment in Multiple Myeloma
- First Posted Date
- 2007-02-06
- Last Posted Date
- 2014-05-12
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 130
- Registration Number
- NCT00431769
Bevacizumab and Bortezomib in Patients With Advanced Malignancy
- Conditions
- Interventions
- First Posted Date
- 2007-01-30
- Last Posted Date
- 2013-02-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 104
- Registration Number
- NCT00428545
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2007-01-29
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 95
- Registration Number
- NCT00428142
- Locations
- 🇨🇦
London Regional Cancer Program, London, Ontario, Canada
🇨🇦Univ. Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada
🇨🇦Humber River Regional Hospital, Toronto, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.